von Redaktion LCGC | Sep. 15, 2012
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal...
von Redaktion LCGC | Sep. 15, 2012
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, and Thomas RK Journal: Clinical Cancer Research, Vol 18, No 17,...
von Redaktion LCGC | Sep. 15, 2012
Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer Heuckmann JM, Rauh D, Thomas RK Journal: Journal of Clinical Oncology, Vol 30, No 27, September 2012, doi: 10.1200/JCO.2012.43.1825Veröffentlichung: September...
von Redaktion LCGC | Juli 15, 2012
Early palliative care for patients with metastatic cancer Gaertner J, Wolf J, Voltz R Journal: Current Opinion in Oncology, Vol 24, No 4, July 2012, doi:10.1097/CCO.0b013e328352ea20Veröffentlichung: Juli...
von Redaktion LCGC | Juli 15, 2012
Predictive value of early and late 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib Kobe C, Scheffler M, Holstein A, Zander T, Nogovam L, Lammertsma AA, Boellaard...
